Here Are the Top 10 In Vitro Diagnostic Companies

Investor Silhouette 2


ROCKVILLE, Md., Oct. 31, 2017 /PRNewswire/ -- A new report from Kalorama Information has detailed the top 10 IVD companies ranked by revenues of clinical diagnostic test instruments, reagents and supplies. Roche Diagnostics is the largest IVD firm in the world, the firm reported that it continues to expand geographically with special emphasis on the top seven emerging countries. Already in second place, Abbott's acquisition of Alere, a sizable force in IVD in its own right, will make the company an undisputable No. 2 in the market, according to the report. Siemens Healthineers took the third spot. The Washington, D.C.-based Danaher came in fourth, driven by acquisitions of Beckman Coulter and Cepheid in recent years. The determination was made based on estimated 2017 revenues in Kalorama Information's new report:The Top 25 IVD Companies, 2017 Revenue Performance, Products, Strategies, Market Activities.

"The top five majors continue to bring innovations to clinical diagnostics. However, of particular interest in the past year or so are the efforts made by smaller concerns in IVDs. These and other companies are translating their portfolio of research-based molecular solution to clinical tools," said Shara Rosen, the report's author.

The report lists the following companies in order of estimated 2017 revenues:

  1. Roche
  2. Abbott
  3. Siemens Healthineers
  4. Danaher
  5. Thermo Fisher
  6. Sysmex
  7. bioMerieux
  8. Ortho Clinical
  9. Bio-Rad
  10. Becton Dickinson

Kalorama notes that there are other companies such as Qiagen and Illumina that are large players in the space but their revenue performance is not wholly clinical diagnostics, according to the report. Other concerns such as Lab Corp and Quest perform test services, so not in the iVD market ranking above but are included in Kalorama's report because of their importance to the market.

"QIAGEN has been pioneering innovation in molecular testing and has recently put new muscle in the diagnosis and monitoring of cancer," Rosen said. "For example, their non-invasive circulating tumor cell and cell free DNA -liquid biopsy. And Bio-Rad announced two of several planned assays that use ddPCR to detect genome edits."

These innovations and other market developments and the most important IVD trends, are included in Kalorama's report.

About Kalorama Information

Kalorama Information, a division of, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on and

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.

Press Contact:
Bruce Carlson
212 807 2262


View original content with multimedia:

SOURCE Kalorama Information


Back to news